Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of subcutaneous afimkibart in moderate to severe active ulcerative colitis
MOH_2026-09-14_017035Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Afimkibart with Placebo (2 arms). Planned start Sep 2026; status: not yet recruiting.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2026-09-14_017035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-14_017035.